|
Giacomo Lanzoni PhD
Assistant Professor, Diabetes Research Institute, Department of Biochemistry and Molecular Biology
University of Miami
USA
|
Dr. Giacomo Lanzoni, PhD, is Assistant Professor at the Diabetes Research Institute and at the Department of Biochemistry and Molecular Biology, University of Miami. Dr. Lanzoni received is PhD from the University of Bologna, Italy, and has gained 17 years of experience in the field of regenerative medicine. He leads a team focused on translational research.
Dr. Lanzoni`s research is focused on regenerative medicine for Type 1 Diabetes and inflammation. He is developing cell-based therapies to modulate immunity, block inflammation, and regenerate tissues.
To modulate immunity, he is utilizing Mesenchymal Stem Cells (MSCs). With his translational and clinical research, he showed that human MSCs robustly inhibit inflammatory responses and determine substantial clinical improvements. Dr. Lanzoni and his team made pioneering observations in a randomized controlled Phase 1/2a clinical trial of MSC treatment in patients with severe COVID-19. MSC appeared to modulate immune responses via multiple mechanisms, blocking master regulators of inflammation and stimulating regulatory cells. Dr. Lanzoni is now developing MSC-based treatments for Type 1 Diabetes, an autoimmune disease, and Chronic Kidney Disease, a disease characterized by persistent inflammation of the kidney.
To regenerate tissues, he harnesses stem and progenitor cells. In this field, he has contributed to the identification of adult progenitor cells in the human biliary tree and pancreas. He is developing novel methods for the transplantation of stem cell derivatives with localized immunomodulation, to inhibit deleterious immune responses and to avoid immune rejection.
Dr. Lanzoni`s research is focused on regenerative medicine for Type 1 Diabetes and inflammation. He is developing cell-based therapies to modulate immunity, block inflammation, and regenerate tissues.
To modulate immunity, he is utilizing Mesenchymal Stem Cells (MSCs). With his translational and clinical research, he showed that human MSCs robustly inhibit inflammatory responses and determine substantial clinical improvements. Dr. Lanzoni and his team made pioneering observations in a randomized controlled Phase 1/2a clinical trial of MSC treatment in patients with severe COVID-19. MSC appeared to modulate immune responses via multiple mechanisms, blocking master regulators of inflammation and stimulating regulatory cells. Dr. Lanzoni is now developing MSC-based treatments for Type 1 Diabetes, an autoimmune disease, and Chronic Kidney Disease, a disease characterized by persistent inflammation of the kidney.
To regenerate tissues, he harnesses stem and progenitor cells. In this field, he has contributed to the identification of adult progenitor cells in the human biliary tree and pancreas. He is developing novel methods for the transplantation of stem cell derivatives with localized immunomodulation, to inhibit deleterious immune responses and to avoid immune rejection.